Global Cancer Therapies Market - Growth, Trends and Forecasts 2017 - 2022

  • ID: 4387356
  • Report
  • Region: Global
  • 211 pages
  • Mordor Intelligence
1 of 3
The global Cancer therapy market is estimated to grow at 17.6% CAGR to reach $38.2bilÌÄ Âion by 2019. Breast cancer therapy is the largestmarket expected to reach $26.8 billion by 2015 at an estimated CAGR of 15%.

Rise in cancer incidences and access to modern therapeutics, population of aged people, Increase in innovations, improvements and approvals promote growth of the market. Furthermore, efficiency and High process magnetize manufactures also contribute to the growth of the market .Major restraints are high price of therapies, change in reimbursement policies, and challenges faced in clinical trials.

Market is segmented based on therapies i. e Targeted cancer therapies ( Hormone therapy, Signal transduction inhibitors, gene expression modulators, Apoptosis inducers etc.), Hormone therapies( Forms of hormone therapy) , immunotherapy( Monoclonal antibodies, Cancer vaccines, Non specific immunotherapies) ,Chemotherapy.

Based on geography market is segmented into North America (US, Canada), Europe, Asia and Rest of the world. Major players are focusing on marketing their products in emerging markets such as India, Japan, Brazil, and China. Oncology spending remain concentrated to America and Europe which totally accounts for 65% of the total market. Targeted therapies have increased their share of global oncology from 11 percent to 46 percent last year.

Major companies in the market include Dendreon, Galena Biopharma, Newlink genetics, Peregrine pharmaceuticals, Inovio pharmaceuticals.

Players are implementing new innovations, strategies, new product launches to gain a competitive edge.

What makes our report Unique?

1) The report discusses what the market is about, current trends in the market and future forecasts of the market. Market share analysis of various companies based on the product and geography.

2) We give you a longest possible segmentation of the market based on products, applications, type of therapies available and geography.

3) High level analysis of the market size, competitive landscape of major players which include mergers & Acquisitions, collaborations, new product launches, and strategies followed to sustain in the market.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1. INTRODUCTION
2. EXECUTIVE SUMMARY
2.1 Cancer drug Market Review
2.2 Research Methodology
3. MARKET DYNAMICS
3.1 Market Drivers
3.1.1 Rise in Cancer Incidences and Access to modern Therapeutics
3.1.1 Population of Aged people
3.1.1 Efficiency and High Price Magnetize manufacturers
3.1.1 Innovations, Improvements and Approvals promote growth
3.2 Market Restraints
3.2.1 High price of therapies
3.2.2 Change in Reimbursement Policies
3.2.3 Challenges encountered in clinical trials
4. Types of Cancer
4.1 Blood Cancer
4.2 Bone Cancer
4.3 Brain Cancer
4.4 Breast Cancer
4.5 Digestive/ Gastrointestinal Cancer
4.6 Endocrine Cancer
4.7 Eye Cancer
4.8 Genitourinary Cancer
4.9 Gynaecologic Cancer
4.10 Head & Neck Cancers
4.11 Respiratory/Lung Cancer
4.12 Skin Cancer
5. Cancer Treatment Types
5.1 Surgery
5.2 Chemotherapy
5.3 Radiation Therapy
5.4 Targeted Therapy
5.5 Immunotherapy (Biologic Therapy)
5.6 Hormonal Therapy
5.7 Hyperthermia
5.8 Stem Cell Transplant
5.9 Other Therapies
6 CANCER THERAPY MARKET
6.1 Global Market Trend
6.2 Market Size and Share Estimation
7. Market Segmentation
7.1 Targeted Cancer Therapeutics
7.1.1 Introduction
7.1.2 Targeted cancer therapy vs Chemotherapy
7.1.3 Targets for targeted cancer therapy
7.1.4 Types of targeted cancer therapies
7.1.4.1 Hormone therapies
7.1.4.2 Signal transduction inhibitors
7.1.4.3 Gene expression modulators
7.1.4.4 Apoptosis inducers
7.1.4.5 Angiogenesis inhibitors
7.1.4.6 Immunotherapies
7.1.4.7 Monoclonal antibodies
7.1.5 Limitations of targeted cancer therapy
7.1.6 Current and future analysis
7.1.7 List of selected targeted therapy drugs
7.1.8 Products in Pipeline
7.1.9 Major players in the market
7.1.9.1 Roche/ Genentech
7.1.9.1.1 Company Profile
7.1.9.1.2 Products in the market
7.1.9.1.3 Financial overview
7.1.9.2 Novartis
7.1.9.2.1 Company Profile
7.1.9.2.2 Products in the market
7.1.9.2.3 Financial overview
7.1.9.3 Bristol-Myers Squibb
7.1.9.3.1 Company Profile
7.1.9.3.2 Products in the market
7.1.9.3.3 Financial overview
7.2 Immunotherapy
7.2.1 Introduction of Immunotherapy
7.2.2 Types of cancer immunotherapies
7.2.2.1 Monoclonal antibodies
7.2.2.1.1 Naked monoclonal antibodies
7.2.2.1.2 Conjugated monoclonal antibodies
7.2.2.1.2.1 Radiolabeled antibodies
7.2.2.1.2.2 Chemolabeled antibodies
7.2.2.2 Cancer vaccines
7.2.2.2.1 Vaccines to help prevent cancer
7.2.2.2.2 Vaccines to help treat cancer
7.2.2.3 Non-specific immunotherapies
7.2.2.3.1 Interferons
7.2.2.3.2 Interleukins.
7.2.3 Current and Future analysis
7.2.4 Limitations of Immunotherapy
7.2.5 List of selected drugs
7.2.6 Major Players in the market
7.2.6.1 Dendreon
7.2.6.1.1 Company Profile
7.2.6.1.2 Products in the market
7.2.6.1.3 Financial overview
7.2.6.2 Galena Biopharma
7.2.6.2.1 Company Profile
7.2.6.2 .2 Products in the market
7.2.6.2 .3 Financial overview
7.2.6.3 NewLink Genetics
7.2.6.3.1 Company Profile
7.2.6.3.2 Products in the market
7.2.6.3.3 Financial overview
7.2.6.4 Peregrine Pharmaceuticals
7.2.6.4.1 Company Profile
7.2.6.4.2 Products in the market
7.2.6.4.3 Financial overview
7.2.6.5 Inovio Pharmaceuticals
7.2.6.5.1Company Profile
7.2.6.5.2Products in the market
7.2.6.5.3 Financial overview
7.3 Hormone Therapy
7.3.1 Introduction of Hormone therapy
7.3.2Aromatase Inhibitors
7.3.3 Selective Estrogen Receptor Modulators
7.3.4 Estrogen Receptors downregulators
7.3.5 Hormone therapy Vs HRT.
7.3.6 Forms of hormone therapy
7.3.6.1 Nasal spray
7.3.6.2 Pills or tablets, taken by mouth
7.3.6.3 Skin gel
7.3.6.4 Skin patches
7.3.6.5 Vaginal creams or vaginal tablets
7.3.6.6 Vaginal ring
7.3.7 Current and future analysis
7.3.8 Products in the current market
7.4 Chemotherapy
7.4.1 Introduction of chemotherapy
7.4.2 Types of agents
7.4.2.1 Alkylating agents
7.4.2.2 Anti-metabolites
7.4.2.3 Anti-microtubule agents
7.4.2.4 Topoisomerase inhibitors
7.4.2.5 Cytotoxic antibiotics
7.4.3 Current and future analysis
7.4.4 Products in market
7.4.5 Chemotherapy regimens
7.4.5.1 Breast Cancer
7.4.5.2 Hodgeking's Disease
7.4.5.3 Germ cell tumor
7.4.5.4 Stomach Cancer
7.4.5.5 Bladder cancer
7.4.5.6 Lung cancer
8 Market Segmentation , Based on Geography
8.1 North America
8.1.1 US
8.1.2 Mexico
8.1.3 Canada
8.2 Europe
8.2.1 UK
8.2.2 France
8.2.3 Germany
8.2.4 Italy
8.2.5 Spain
8.3 Asia-Pacific
8.3.1 India
8.3.2 China
8.3.3 Japan
9. Competitive landscape
9.1 Introduction
9.2 New Product Launch
9.3 Strategic development
9.4 Mergers, Acquisitions
9.5 Market Share Analysis
10. Company Profiles
10.1 ASTRAZENECA PLC
10.2 CHUGAI PHARMACEUTICAL CO., LTD.
10.3 GENENTECH INC.
10.4 GLAXOSMITHKLINE PLC
10.5 GPC BIOTECH AG
10.6 OSI PHARMACEUTICALS, INC.
11. Appendix
11.1. Abbreviations
11.2. Sources
11.3. Bibliography
11.4. Disclaimer
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll